The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification, J Thorac Oncol, vol.10, pp.1243-60, 2015. ,
Drug resistance to molecular targeted therapy and its consequences for treatment decisions in non-small-cell lung cancer, Front Oncol, vol.4, p.190, 2014. ,
Mammalian cyclin-dependent kinases, Trends Biochem Sci, vol.30, pp.630-671, 2005. ,
Cyclin-dependent kinases: a family portrait, Nat Cell Biol, vol.11, pp.1275-1281, 2009. ,
Cyclin D as a therapeutic target in cancer, Nat Rev Cancer, vol.11, pp.558-72, 2011. ,
Cyclin D1 in non-small cell lung cancer: a key driver of malignant transformation, Lung Cancer, vol.55, pp.1-14, 2007. ,
Overexpression of cdk4/cyclin D1, a possible mediator of apoptosis and an indicator of prognosis in human primary lung carcinoma, Int J Cancer, vol.110, pp.532-573, 2004. ,
A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma, Cancer Cell, vol.18, pp.63-73, 2010. ,
The history and future of targeting cyclin-dependent kinases in cancer therapy, Nat Rev Drug Discov, vol.14, pp.130-176, 2015. ,
Targeting cyclin-dependent kinases in human cancers: from small molecules to Peptide inhibitors, Cancers (Basel), vol.7, pp.179-237, 2015. ,
Cell cycle kinases as therapeutic targets for cancer, Nat Rev Drug Discov, vol.8, pp.547-66, 2009. ,
Peptides or small molecules? Different approaches to develop more effective CDK inhibitors, Curr Med Chem, vol.18, pp.2854-66, 2011. ,
ATP-noncompetitive CDK inhibitors for cancer therapy: an overview, Expert Opin Investig Drugs, vol.22, pp.895-906, 2013. ,
Targeting cyclin-dependent kinases in anti-neoplastic therapy, Curr Opin Cell Biol, vol.25, pp.772-781, 2013. ,
Molecular pathways: CDK4 inhibitors for cancer therapy, Clin Cancer Res, vol.20, pp.3379-83, 2014. ,
Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy, J Natl Cancer Inst, vol.104, pp.476-87, 2012. ,
Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors, Cancer Discov, vol.6, pp.740-53, 2016. ,
Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer, Cancer Res, vol.76, pp.2301-2314, 2016. ,
Small-molecule kinase inhibitors: an analysis of FDA-approved drugs, Drug Discov Today, vol.21, pp.5-10, 2016. ,
Palbociclib resistance confers dependence on an FGFR-MAP kinase-mTOR-driven pathway in KRAS-mutant non-small cell lung cancer, Oncotarget, vol.9, pp.31572-89, 2018. ,
Inhibition of protein-protein interactions using designed molecules, Chem Soc Rev, vol.38, pp.3289-300, 2009. ,
Small molecules, big targets: drug discovery faces the protein-protein interaction challenge, Nat Rev Drug Discov, vol.15, pp.533-50, 2016. ,
Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix, Science, vol.305, pp.1466-70, 2004. ,
A stapled BID BH3 helix directly binds and activates BAX, Mol Cell, vol.24, pp.199-210, 2006. ,
A cell-penetrating helical peptide as a potential HIV-1 inhibitor, J Mol Biol, vol.378, pp.565-80, 2008. ,
Reactivation of the p53 tumor suppressor pathway by a stapled p53 peptide, J Am Chem Soc, vol.129, pp.2456-2463, 2007. ,
Direct inhibition of the NOTCH transcription factor complex, Nature, vol.462, pp.182-190, 2009. ,
Phase I trial of a novel stapled peptide ALRN-6924 disrupting MDMX-and MDM2-mediated inhibition of WT p53 in patients with solid tumors and lymphomas, Journal of Clinical Oncology, vol.35, p.2505, 2017. ,
Phase 2a study of a novel stapled peptide ALRN-6924 disrupting MDMX-and MDM2-mediated inhibition of wild-type TP53 in patients with peripheral t-cell lymphoma, Ann Oncol, vol.28, pp.355-71, 2017. ,
Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex, Nature, vol.376, pp.313-333, 1995. ,
Kinetic mechanism of activation of the Cdk2/cyclin A complex. Key role of the C-lobe of the Cdk, J Biol Chem, vol.277, pp.23847-53, 2002. ,
Design of a novel class of peptide inhibitors of cyclin-dependent kinase/cyclin activation, J Biol Chem, vol.280, pp.13793-800, 2005. ,
Adequacy of CT-guided biopsies with histomolecular subtyping of pulmonary adenocarcinomas: influence of ATS/ERS/IASLC guidelines, Lung Cancer, vol.82, pp.69-75, 2013. ,
Identification of a novel complex BRAF mutation associated with major clinical response to vemurafenib in a patient with metastatic melanoma, JAMA Dermatol, vol.149, pp.1403-1409, 2013. ,
Insulin-like growth factor-1 receptor inhibition overcomes gefitinib resistance in mucinous lung adenocarcinoma, The Journal of pathology, vol.225, pp.83-95, 2011. ,
URL : https://hal.archives-ouvertes.fr/inserm-00598462
Synthesis of conformationally restricted amino acids and peptides employing olefin matathesis, J Am Chem Soc, vol.117, pp.5855-5861, 1995. ,
Application of ring-closing metathesis to the synthesis of rigidified amino acids and peptides, J Am Chem Soc, vol.118, pp.9606-9620, 1996. ,
Highly Efficient Synthesis of Covalently Cross-Linked Peptide Helices by Ring-Closing Metathesis, Angew Chem Int Ed Engl, vol.37, pp.3281-3285, 1998. ,
Towards understanding cell pemetration by stapled peptides, Med Chem Commun, vol.6, pp.111-120, 2015. ,
Hydrocarbon-stapled peptides: principles, practice, and progress, J Med Chem, vol.57, pp.6275-88, 2014. ,
Synthesis and biophysical characterization of stabilized alpha-helices of BCL-2 domains, Methods Enzymol, vol.446, pp.369-86, 2008. ,
An all-hydrocarbon cross-linking system for enhancing the helicity and metabolic stability of peptides, J Am Chem Soc, vol.122, pp.5891-5893, 2000. ,
Stapled peptides for intracellular drug targets, Methods Enzymol, vol.503, pp.3-33, 2012. ,
TP-2Rho Is a Sensitive Solvatochromic Red-Shifted Probe for Monitoring the Interactions between CDK4 and Cyclin D, Chembiochem, vol.17, pp.737-781, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-02009852
Fluorescent peptide biosensor for monitoring CDK4/cyclin D kinase activity in melanoma cell extracts, mouse xenografts and skin biopsies, Biosens Bioelectron, vol.85, pp.371-80, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01905259
Fluorescent Biosensor for Detection of the R248Q ,
URL : https://hal.archives-ouvertes.fr/hal-02009856
, Aggregation-Prone Mutant of p53, Chembiochem, vol.20, pp.605-618, 2019.
Anti-tumor efficacy of hyaluronan-based nanoparticles for the co-delivery of drugs in lung cancer, Journal of controlled release : official journal of the Controlled Release Society, vol.275, pp.117-145, 2018. ,
URL : https://hal.archives-ouvertes.fr/hal-02151669
Targeting CD44 receptor-positive lung tumors using polysaccharide-based nanocarriers: Influence of nanoparticle size and administration route, Nanomedicine, vol.12, pp.921-953, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01360462
In vivo mice lung tumor follow-up with fluorescence diffuse optical tomography, J Biomed Opt, vol.13, p.11008, 2008. ,
URL : https://hal.archives-ouvertes.fr/inserm-00313764
Near-infrared optical guided surgery of highly infiltrative fibrosarcomas in cats using an anti-alphavss3 integrin molecular probe, Cancer Lett, vol.334, pp.188-95, 2013. ,
Crystal structure of human CDK4 in complex with a D-type cyclin, Proc Natl Acad Sci, vol.106, pp.4166-70, 2009. ,
DrugScorePPI webserver: fast and accurate in silico alanine scanning for scoring protein-protein interactions, Nucleic Acids Res, vol.38, pp.480-486, 2010. ,
Cell cycle kinases in cancer, Curr Opin Genet Dev, vol.17, pp.60-65, 2007. ,
Cell cycle, CDKs and cancer: a changing paradigm, Nat Rev Cancer, vol.9, pp.153-66, 2009. ,
Molecular Pathways: Targeting the Cyclin D-CDK4/6 Axis for Cancer Treatment, Clin Cancer Res, vol.21, pp.2905-2915, 2015. ,
Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine, Invest New Drugs, vol.32, pp.825-862, 2014. ,
Treatment Rationale and Study Design for the JUNIPER Study: A Randomized Phase III Study of Abemaciclib With Best Supportive Care Versus Erlotinib With Best Supportive Care in Patients With Stage IV Non-Small-Cell Lung Cancer With a Detectable KRAS Mutation Whose Disease Has Progressed After Platinum-Based Chemotherapy, Clin Lung Cancer, vol.17, pp.80-84, 2016. ,
Cyclin-Dependent Kinase 4/6 Inhibitors for the Treatment of Breast Cancer: A Review of Preclinical and Clinical Data, Clin Breast Cancer, vol.16, pp.8-17, 2016. ,
Inhibition of alpha-helix-mediated protein-protein interactions using designed molecules, Nat Chem, vol.5, pp.161-73, 2013. ,
Using Peptidomimetics and Constrained Peptides as Valuable Tools for Inhibiting Protein(-)Protein Interactions, Molecules, p.23, 2018. ,
Nebulized Gadolinium-Based Nanoparticles: A Theranostic Approach for Lung Tumor Imaging and Radiosensitization, Small, vol.11, pp.215-236, 2015. ,
URL : https://hal.archives-ouvertes.fr/hal-01115895
Fate of inhaled monoclonal antibodies after the deposition of aerosolized particles in the respiratory system, Journal of controlled release : official journal of the Controlled Release Society, vol.196, pp.344-54, 2014. ,
URL : https://hal.archives-ouvertes.fr/hal-02376374
Mechanisms of drug combinations: interaction and network perspectives, Nat Rev Drug Discov, vol.8, pp.111-139, 2009. ,
CDK4/6 Inhibitors: What Is the Best Cocktail?, Clin Cancer Res, vol.25, pp.6-8, 2019. ,
CDK4 protein is degraded by anaphase-promoting complex/cyclosome in mitosis and reaccumulates in early G1 phase to initiate a new cell cycle in HeLa cells, J Biol Chem, vol.292, pp.10131-10172, 2017. ,